Xponance’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Xponance’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,022	Closed	-$230K	–	1302
2023 Q1	$230K	Sell	3,022 -341	-10%	-$28.3K	﹤0.01%	1099
2022 Q4	$279K	Sell	3,363 -522	-13%	-$42.3K	﹤0.01%	1049
2022 Q3	$308K	Sell	3,885 -2,205	-36%	-$186K	0.01%	989
2022 Q2	$452K	Hold	6,090	–	–	0.01%	894
2022 Q1	$547K	Hold	6,090	–	–	0.01%	866
2021 Q4	$682K	Hold	6,090	–	–	0.01%	777
2021 Q3	$766K	Hold	6,090	–	–	0.01%	683
2021 Q2	$825K	Hold	6,090	–	–	0.02%	677
2021 Q1	$826K	Sell	6,090 -1,333	-18%	-$200K	0.02%	552
2020 Q4	$1.04M	Hold	7,423	–	–	0.02%	450
2020 Q3	$827K	Buy	+7,423	New	+$832K	0.02%	474

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Xponance's XBI Position: Q2 2023 in Review

Xponance sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 3,022 shares — an estimated $230K sold.

Xponance first reported a position in XBI in Q3 2020 and held it in 11 quarters. The position peaked at $1.04M in Q4 2020. 713 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Xponance reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Xponance sold 3,022 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $230K.
Xponance first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 11 quarters.
Xponance's State Street SPDR S&P Biotech ETF position peaked at $1.04M in Q4 2020.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Xponance's 13F filing for Q2 2023, filed 14 Jul 2023.